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Clinical Relevancy Statement
Intravenous lipid emulsions are an integral part of the 
parenteral nutrition regimen in preterm neonates. A substan-
tial body of evidence indicates that a well-balanced fatty acid 
supply during the neonatal period is a crucial factor influenc-
ing outcome criteria such as growth, visual development, and 
cognitive development. In this study, a lipid emulsion con-
taining fish oil, olive oil, medium-chain triglycerides, and 
soybean oil was found to be well tolerated in preterm infants, 
Background: For premature neonates needing parenteral nutri-
tion (PN), a balanced lipid supply is crucial. The authors 
hypothesized that a lipid emulsion containing medium-chain 
triglycerides (MCTs) and soybean, olive, and fish oils would be 
as safe and well tolerated as a soybean emulsion while benefi-
cially influencing the fatty acid profile. Methods: Double-blind, 
controlled study in 53 neonates (<34 weeks’ gestation) rand-
omized to receive at least 7 days of PN containing either an 
emulsion of MCTs and soybean, olive, and fish oils or a soy-
bean oil emulsion. Target lipid dosage was 1.0 g fat/kg body 
weight [BW]/d on days 1–3, 2 g/kg BW/d on day 4, 3 g/kg BW/d 
on day 5, and 3.5 g/kg BW/d on days 6–14. Results: Test emul-
sion vs control, mean ± SD: baseline triglyceride concentra-
tions were 0.52 ± 0.16 vs 0.54 ± 0.19 mmol/L and increased 
similarly in both groups to 0.69 ± 0.38 vs 0.67 ± 0.36 on day 8 of 
treatment (P = .781 for change). A significantly higher decrease in 
total and direct bilirubin vs baseline was seen in the test group 
compared with the control group P < .05 between groups). In 
plasma and red blood cell phospholipids, eicosapentaenoic acid 
and docosahexaenoic acid were higher, and the n-6/n-3 fatty acid 
ratio was lower in the test group (P < .05 vs control). Conclusions: 
The lipid emulsion, based on a mixture of MCTs and soybean, 
olive, and fish oils, was safe and well tolerated by preterm infants 
while beneficially modulating the fatty acid profile. (JPEN J 
Parenter Enteral Nutr. 2012;36:81S-94S)
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and n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) 
were significantly increased. The higher availability of n-3 
LC-PUFAs with this lipid might be considered advantageous 
with regard to their postulated role in ensuring adequate 
brain and retinal development in preterm infants and the 
postulated anti-inflammatory and immunomodulatory role.
Introduction
Preterm neonates, having missed the crucial period of 
intrauterine nutrient accretion and storage, possess only 
limited energy and fat reserves.
1,2 When enteral feeding is 
not tolerated or insufficient to meet the requirements, 
parenteral nutrition (PN) must be instituted shortly after 
birth.
2 Intravenous lipid emulsions are an integral part of 
the PN regimen in neonates.
2-4 A substantial body of evi-
dence indicates that a well-balanced fatty acid supply 
during the neonatal period is a crucial factor influencing 
outcome criteria such as growth, visual development, and 
cognitive development.
2,5,6 Yet, most commonly used soy-
bean oil–based lipid emulsions contain high amounts of 
linoleic acid (LA; C18:2 n-6) relative to α-linolenic acid 
(α-LNA; C18:3 n-3) but low amounts of arachidonic acid 
(AA; C20:4 n-6) and no n-3 long-chain polyunsaturated 
fatty acids (LC-PUFAs) such as eicosapentaenoic acid 
(EPA; C20:5 n-3) and docosahexaenoic acid (DHA C22:6 
n-3). The need for more appropriate lipid emulsions in 
pediatric and neonatal care, however, has been recog-
nized.
7 In enteral feeding studies, LC-PUFAs have been 
shown to positively influence neurological and mental 
development in both preterm and term infants.
8-10 It has 
been demonstrated that feeding preterm infants formulas 
containing DHA and AA enhances growth and improves 
mental and psychomotor development scores as well as 
visual acuity.
8,11 EPA functions as a precursor for the 
LC–fatty acid synthesized in the retina.
12 Consequently, it 
has been postulated that LC-PUFAs are important for 
growth and development of preterm and term infants.
5
In the present prospective, double-blind, randomized, 
parallel, controlled study, the safety, tolerability, and efficacy 
of a test lipid emulsion (SMOFlipid 20%; Fresenius Kabi, 
Bad Homburg, Germany) were evaluated in premature neo-
nates as compared to a conventional soybean oil emulsion. 
The emulsion under investigation contains a physical mix-
ture of 4 different lipid sources: soybean oil providing LA 
and α-LNA for essential fatty acid supply; olive oil rich in 
monounsaturated fatty acids (MUFAs), which are less sus-
ceptible to lipid peroxidation than PUFAs; medium-chain 
triglycerides (MCTs) showing a faster metabolic clearance 
than long-chain triglycerides; and fish oil for the supply of 
n-3 LC-PUFA EPA and DHA.
13-17
Our primary hypothesis was that the test treatment 
would be as safe and well tolerated as a standard soy-
bean emulsion with regard to the serum concentration 
of triglycerides, hematological and clinical laboratory 
parameters, adverse events (AE) profile, tolerability, and 
vital signs. Furthermore, we intended to provide documen-
tary evidence that the test emulsion is equally efficient as 
a standard soybean emulsion in promoting the neonates’ 
growth while beneficially influencing the fatty acid profile 
in plasma and red blood cell (RBC) phospholipids.
Methods
Patients and Randomization
Between November 2004 and February 2006, 53 prema-
ture neonates were enrolled at the Department of 
Neonatology of the University Hospital Leuven, Belgium. 
Study protocol, patient information, and informed con-
sent forms were approved by the local Ethical Committee 
of the University Hospitals, Leuven, Belgium. The study 
was performed in accordance with the International 
Conference on Harmonisation (ICH) guidelines for Good 
Clinical Practice (GCP), the legal provisions of the cur-
rent version of the local drug law, the European 
Community GCP-Guidelines, and the ethical principles 
of the current version of the Declaration of Helsinki as 
revised in Edinburgh 2000.
Infants were randomly assigned to one of the treat-
ment groups following the pattern of a randomization list 
generated prior to study start by using the software 
RANCODE by idv (Institute for Data Analysis and Trial 
Planning, Gauting, Germany). Within each block, the 
number of infants allocated to each of the 2 treatments 
was balanced. The randomization was stratified with 
regard to birth weight at the time of inclusion (500–1000 
g, 1001–1500 g, 1501–2000 g). Infants with a gestational 
age <34 weeks, birth weights between 500 and 2000 g, 
and an estimated requirement of PN of at least 7 days 
were to be included. Adhering to the general safety consid-
erations, we excluded extremely immature neonates and/or 
those with the following abnormalities requiring therapeu-
tic interventions that would interfere with the treatment 
regimen: severe congenital malformations, congenital 
heart failure, anuria due to circulation failure, liver/hemo-
lytic disease, thrombocytopenia, oxygen saturation SO2 
<80% longer than 2 hours, previous inclusion in other tri-
als, severe acidosis, application of catecholamines, multio-
rgan failure, or hypoxic-ischemic encephalopathy.
Written informed consent was obtained from the 
parents before enrollment; parents received detailed 
information about aims and risks of the study and had the 
right to withdraw their child from the study at any time.
Interventions
Infants received PN containing either SMOFlipid 20% 
(test group; n = 26) or a conventional soybean oil emul-
sion (Intralipid 20%, control group; n = 27), both from Lipid Emulsion of Soybean, Olive, and Fish Oils and MCT in Preterm Infants / Rayyan et al  83S
Fresenius Kabi, for at least 7 consecutive days and up to 
14 days. To ensure blinding, the study and control infu-
sions were of the same size and identical appearance. 
Infusions prepared in the hospital pharmacy and provided 
to the unit could be identified only by the patient number 
printed on the outside of the packaging. The PN regimens 
were infused via peripheral vein (n = 4), central venous 
catheter (CVC; n = 43), or peripheral vein and CVC (n = 
6). Eligible patients should have received the 20% lipid 
emulsions separately as 1 component of PN by continu-
ous infusion at a maximum rate of 0.17 g fat/kg body 
weight [BW]/h over a recommended period of 20–24 
hours per day.
2,4 Yet, according to patients’ individual 
requirements and because of hospital routines, the actual 
period of infusion amounted to 18 h/d. This regimen 
started on study day 1 and was continued for at least 7 
consecutive days and up to 14 days.
The daily target dosage of fat started at 1.0 g fat/kg 
BW/d on days 1–3 and was increased to 2 g/kg BW/d on 
day 4, 3 g/kg BW/d on day 5, and 3.5 g/kg BW/d from day 
6 on. Table 1 shows the parenteral fat intake day by day. 
The maximum dose of 3.5 g/kg BW/d is in accordance 
with the recommendations for maximum fat intake in 
infants as published by the European Society for Clinical 
Nutrition and Metabolism (ESPEN)/European Society of 
Paediatric Gastroenterology, Hepatology, and Nutrition 
(ESPGHAN) in 2005.
2 When serum triglyceride levels 
exceeded 300 mg/dL (3.43 mmol/L), the dosage was 
reduced by steps of 0.5 g fat/kg BW according to the 
clinical condition. Composition and α-tocopherol content 
of the investigational products are given in Table 2. Fatty 
acid profiles of the lipid compositions under investigation 
are provided in Table 3. Other components of PN were 
given as standardized solutions at the discretion of the 
investigator.
18 Additional enteral intake comprising <30% 
of the total lipid intake on days 1–3, <50% on days 4–7, 
and <70% on days 8–14 of the total energy intake was 
permitted if appropriate and documented.
Each patient was assigned a patient number at the 
time of inclusion, and the amount of fat for infusion was 
calculated. During the prestudy period (day 0), signed 
parents’ informed consent was obtained, eligibility was 
assessed, and demographic data, medical history, concomitant 
diseases, and medications of the neonates were recorded. 
Clinical assessments (heart rate, temperature, blood pressure, 
body weight, oxygen therapy) were performed daily from day 
0 (prestudy visit) until study termination, either on day 15 
or following the last infusion of study treatment (post-
treatment). Body height was assessed at birth and post-
treatment. At the prestudy visit (baseline) and on days 5, 
8, and 15 during the study period, blood samples for 
assessment of triglycerides, other lipid parameters (total, 
Table 1.  Parenteral Fat Intake (g/kg Body Weight), Intent-to-Treat Population
n Test Group (SMOFlipid) n Control Group
Day 1 26 1.0 (0.2) 27 1.0 (0.1)
Day 2 26 1.0 (0.1) 27 1.0 (0.2)
Day 3 25 1.0 (0.2) 26 1.0 (0.2)
Day 4 24 2.0 (0.2) 25 2.0 (0.2)
Day 5 24 2.9 (0.4) 25 3.0 (0.4)
Day 6 24 3.4 (0.5) 23 3.3 (0.5)
Day 7 23 3.3 (0.5) 23 3.3 (0.8)
Day 8 8 3.3 (0.2) 11 3.3 (0.2)
Day 9 8 3.3 (0.3) 9 3.3 (0.2)
Day 10 6 2.9 (1.1) 8 3.3 (0.2)
Day 11 5 3.2 (0.1) 6 3.2 (0.2)
Day 12 5 3.1 (0.1) 6 3.2 (0.3)
Day13 3 3.0 (0.2) 4 3.2 (0.3)
Day 14 3 3.1 (0.3) 2 3.2 (0.6)
Values are presented as mean (SD).
Table 2.  Composition of SMOFlipid 20% and 
Intralipid 20%
SMOFlipid  
20%
Intralipid  
20%
Soybean oil, g/L 60 200
Medium-chain triglycerides, g/L 60 —
Olive oil, g/L 50 —
Fish oil, g/L 30 —
Vitamin E, mg α-tocopherol/L Approx. 200 38
Egg phospholipids, g/L 12 12
Glycerol, g/L 25 22.5
Water for injection ad 1000 mL ad 1000 mL
PH value 7.5–8.8 7–8
Osmolarity, mosmol/L 273 265
Reprinted with permission from Fresnius Kabi.84S  Journal of Parenteral and Enteral Nutrition / Vol. 36, Suppl. 1, January 2012
high-density lipoprotein [HDL], and low-density lipopro-
tein [LDL] cholesterol), electrolytes, glucose, and liver 
enzymes were drawn. Baseline samples for the assess-
ment of hematological parameters and bilirubin were 
drawn on day 3 and for creatinine on day 5. AEs and 
serious adverse events (SAEs) were defined in accord-
ance with the ICH, and their possible relation to study 
treatment was documented until 1 day after the end of 
the last study infusion. The reporting period for SAEs 
ended 6 days after the end of the last study infusion. 
All subjects were followed up until discharge. Blood 
samples for assessing plasma and RBC phospholipid 
fatty acid pattern and plasma phospholipids were drawn 
at baseline (pretreatment) and 4 hours after the last 
study infusion (posttreatment). The primary safety 
parameter was the change in the concentration of 
serum triglycerides (mmol/L) from baseline to day 8; 
secondary safety criteria included hematological and 
clinical laboratory parameters, AE profile, tolerability, 
and vital signs. Primary efficacy criteria were the 
change in body weight from study day 1 to day 8 and 
height from birth length to last observation. 
Furthermore, days on mechanical ventilation/oxygen 
therapy and the change in plasma and RBC fatty acid 
pattern were to be evaluated.
Analytical Methods
Methods of Sample Preparation and Storage
Blood samples were collected by venous puncture or arte-
rial line. All determinations of routine laboratory assess-
ments, including triglycerides, were assessed using 
established validated standard techniques. Analyses were 
performed by the Clinical Laboratories of the University 
Hospitals Leuven. These laboratories undergo regular 
external validation (Good Laboratory Practice) and evalu-
ation (BELAC, Belgian Accreditation Body).
Blood samples for fatty acid determination were cen-
trifuged (15 minutes, 3500 rpm), and plasma was subse-
quently separated from the cellular fraction. Following 
removal of the buffy coat, both the plasma and the RBC 
fraction were stored at –70°C until analysis. Plasma and 
RBC fatty acids were assessed by gas chromatography/
mass spectrometry and displayed as relative amounts (% 
of total fatty acids).
19
Statistical Analysis
All statistical analyses were performed for the intention-
to-treat (ITT) population. Homogeneity of baseline char-
acteristics was evaluated by means of the Wilcoxon 
2-sample test (t approximation). Within-group compari-
son of changes from baseline was carried out by means of 
the 2-sided Wilcoxon signed rank test and based on sub-
jects with pairwise data only; between-groups compari-
sons were carried out by means of the Wilcoxon test. 
Results are presented as mean ± SD. The level of signifi-
cance was set at P < .05.
The aim of the primary analysis was to show noninfe-
riority of the test treatment compared to controls. Test of 
noninferiority was performed using a confidence limit 
approach applying the 1-sided Wilcoxon-Mann-Whitney 
test for noninferiority. As a reasonable benchmark, the 
lower equivalence margin was defined as a Mann-Whitney 
estimator (MW) = 0.38. If the lower bound (LB) of the 
1-sided 95% confidence interval (CI-LB) is >0.38, then 
noninferiority is proven in a confirmatory way up to this 
narrow margin.
20,21
The primary end point was the safety parameter 
serum triglycerides, which were evaluated as a change 
from baseline to day 8. In case the study was discontinued 
before study day 8, missing values were replaced by means 
of the “last value carried forward” (LVCF) procedure from 
day 5. Treatment groups were compared by using differ-
ences of means and their confidence bounds calculated by 
least squares means from analysis of variance (ANOVA) 
with adjustment for baseline and covariates. The primary 
efficacy criteria of body weight and body length were evalu-
ated as change (g) from day 1 to day 8 (LVCF) and change 
from birth length (cm) to last observation, respectively. 
Between-group differences were evaluated by calculating 
least squares means (ANOVA) of change from baseline 
adjusted for baseline and covariates.
The time to end artificial or supportive ventilation over 
the whole treatment period was evaluated descriptively by 
Kaplan-Meyer curves, and the differences between treat-
ment groups were evaluated using the Peto log-rank test. 
The Cox regression model was used for the adjustment for 
Table 3.  Fatty Acid Profiles of SMOFlipid 20% and 
Intralipid 20%
a
SMOFlipid  
20%
Intralipid  
20%
Caprylic acid C 8:0 16.3 —
Caproic acid C 10:0 11.4 —
Palmitic acid C 16:0 9.2 11
Stearic acid C18:0 2.7 4
Oleic acid C18:1 ω-9 27.8 24
Linoleic acid C 18:2 ω-6 18.7 53
α-Linolenic acid C 18:3 ω-3 2.4 8
Stearidonic acid C 18:4 ω-3 0.4 —
Arachidonic acid C 20:4 ω-6 0.5 —
Eicosapentaenoic acid C 20:5 ω-3 2.4 —
Docosapentaenoic acid C 22:5 ω-3 0.3 —
Docosahexaenoic acid C 22:6 ω-3 2.2 —
Others 5.7 —
Ratio ω-6/ω-3 2.5:1 7:1
aPercentage of fatty acids (wt/wt), mean values, reprinted with 
permission from the manufacturer, Fresenius-Kabi.Lipid Emulsion of Soybean, Olive, and Fish Oils and MCT in Preterm Infants / Rayyan et al  85S
stratum/birth weight. Unless indicated otherwise, fatty 
acids, biochemical and hematological parameters, and vital 
signs were evaluated as median changes from baseline/day 
3 (for hematological parameters) to day 8.
Results
Participant Flow
All 53 neonates received at least 1 dose of study medica-
tion and had at least 1 safety assessment afterward. All 
patients were included in the ITT population, which was 
identical to the safety population. In total, 16/17 (test/
control group) infants had at least 1 protocol deviation. 
Most frequent reasons included “enteral nutrition with 
more than 20% of total energy intake at the beginning of 
lipid supplementation” (12/12), “study treatment compli-
ance not at least 80% in 6 out of 7 treatment days during 
the main study phase” (3/3), and “premature termination 
during the main study phase” (2/3); the latter two were 
regarded as major protocol deviations leading to exclusion 
from the per-protocol (PP) population analysis, which 
was the case in 7 patients (3/4). Reasons for exclusion 
were “not compliant” (1/1) “adverse event and not com-
pliant” (1/1), “worsening of disease and not compliant” 
(1/0), “worsening of disease and adverse event” (0/1), and 
“consent withdrawn and not compliant” (0/1). An over-
view of the participant flow is presented in Figure 1.
Importantly, infants’ recovery during the main study 
(no need for further PN) was not regarded as a major 
protocol violation. The PP data set comprised 46 infants. 
According to the definition of the study period (minimum 
7 days, up to 14 days), the number of study patients 
decreased rapidly after study day 7. A main study phase 
was defined as the period from the day of inclusion until 
completion of treatment day 7 (baseline to day 8) and the 
complete study phase up to day 15 as a maximum.
 
53 pa￿ents enrolled
53 pa￿ents randomized
26 assigned test group 
(SMOFlipid)
27 assigned control
(Intralipid)
26 received medica￿on and follow-up 
available (safety/ITT analysis)
27 received medica￿on and follow-up 
available (safety/ITT analysis)
3 premature discon￿nua￿ons/major 
protocol viola￿ons
4 premature discon￿nua￿ons/major 
protocol viola￿ons
23 per-protocol (PP) analysis  23 per-protocol (PP analysis) 
Figure 1.  Trial profile and participant flow. The number of 
patients and the actual study profile are shown in each block. A 
total of 53 patients were randomized, and all 53 patients were 
included in the safety and primary efficacy analysis (intention-
to-treat population). The per-protocol (PP) analysis comprised 
46 patients. ITT, intention to treat.
Table 4.  Overview of Baseline Demographic and Clinical Characteristics: Intention-to-Treat Population
n
Test Group 
(SMOFlipid) n Control Group
P Value  
(Test of Homogeneity)
a
Gestational age, wk, mean (SD) 26 29.9 (1.9) 27 30.4 (1.8) .195
Age at start of infusion, d, mean (SD) 26 7.0 (1.4) 27 7.3 (2.0) .464
Gender, % of females 26 69.2 27 40.7 .054
b
Birth length, cm, mean (SD) 25 38.9 (3.8) 25 39.1 (3.2) .371
Birth weight, g, mean (SD) 27 1335.6 (408.8) 27 1364.1 (339.7) .440
Head circumference, cm, mean (SD) 25 27.6 (2.7) 23 27.5 (2.0) .356
Apgar score, 60 seconds, No. (%) .683
c
 >8 26 11 (42.3) 27 9 (33.3)
 6–8 26 10 (38.5) 27 13 (48.1)
 <6 26 5 (19.2) 27 5 (18.5)
Apgar score, 300 seconds, No. (%) .885
c
 >8 26 16 (61.5) 27 15 (55.6)
 6–8 26 9 (34.6) 27 12 (44.4)
 <6 26 1 (3.8) 27 0
aWilcoxon 2-sample test (t approximation).
bFisher exact test.
cMantel-Haenszel test.86S  
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Baseline Data
Baseline characteristics were comparable between the 
treatment groups (Table 4); the only significant difference 
was a markedly higher rate of female neonates in the test 
group as compared to the control group (69.2% vs 40.7%; 
P = .054). Infants in the test group were slightly more 
immature with regard to gestational age, body weight, and 
length and the age at the start of infusions. Both treat-
ment groups were comparable with respect to physical 
examination results at baseline and previous medication 
(data not shown). Main diagnoses in the study/control 
group were “respiratory distress syndrome” in 21/22 
infants and “difficulties to adaptation,” meaning transient 
tachypnea of the newborn, in 18/17 infants. Treatment 
groups did not differ with respect to the exposure to study 
drug and nutrient intake during the main and complete 
study phase (Table 5), and total parenteral fat intake per 
kg body weight was in accordance with the study proto-
col. Maximal parenteral fat intake was 3.4 g/kg BW/d in 
the SMOFlipid group and 3.3 g/kg BW/d in the Intralipid 
group. Two infants received PN exclusively. For the other 
patients, the enteral nutrition (EN) part of the nutrition 
consisted of expressed breast milk in 15 patients, formula 
in 13 patients, and combined expressed breast milk and 
formula in 23 patients.
Primary Outcome Measures
On day 8, triglyceride levels were increased in both treat-
ment groups vs baseline (see Table 6) and were signifi-
cant in the test group only (P < .05). Yet, there was no 
significant difference between treatment groups with 
Table 6.  Clinical Laboratory and Lipid Parameters at Baseline and on Day 8 (After the Main Study Phase): 
Intention-to-Treat Population
Baseline Day 8 P
a P
b
n
Test Group 
(SMOFlipid) n
Control 
Group n
Test Group 
(SMOFlipid) n Control Group
Test vs 
Control
Test  
Group 
(SMOFlipid)
Control 
Group
Hemoglobin, g/dL
c 25 13.0 (1.87) 24 12.9 (2.08) 12 11.8 (2.02) 13 12.1 (2.16) .276 .001 .002
Hematocrit, %
c 25 36.6 (4.79) 24 36.4 (5.22) 12 33.5 (5.56) 13 34.9 (5.94) .468 .003 .002
Red blood cells, 10
12/L
c 25 3.7 (0.51) 24 3.6 (0.52) 12 3.4 (0.53) 13 3.5 (0.50) .235 .003 .002
White blood cells, 10
9/L
c 25 14.6 (5.16) 24 12.0 (3.18) 12 12.7 (2.43) 13 9.8 (3.14) .176 .029 .322
Platelets, 10
9/L
c 25 406.2 (133.27) 24 370.5 (144.75) 12 477.1 (116.49) 13 454.5 (176.65) .817 .007 .084
ALT, IU/L 25 6.0 (1.57) 25 6.4 (1.64) 21 9.8 (4.83) 21 9.2 (4.11) .888 .003 .008
GGT, IU/L 24 89.8 (55.37) 19 71.0 (47.42) 21 73.1 (33.99) 18 63.0 (44.30) .135 .126 .465
Direct bilirubin 19 22 19 22 .036 .347 .022
 µmol/L
c, d 12.48 (7.2) 8.04 (5.6) 10.26 (5.8) 12.83 (7.2)
 mg/dL 0.73 (0.42) 0.47 (0.33) 0.6 (0.34) 0.75 (0.42)
Total bilirubin 26 27 19 24 .049 <.001 .137
 µmol/L
c, d 127.6 (70.82) 115 (47.26) 94.8 (68.18) 98.2 (74.69)
 mg/dL 7.46 (4.14) 6.73 (2.76) 5.54 (3.99) 5.74 (4.37)
Creatinine
e 25 70.9 (12.36) 26 70.7 (10.45) 16 63.3 (4.83) 13 67.3 (8.09) .614 .003 .003
CRP, mg/L 26 1.4 (1.09) 27 2.0 (3.42) 21 2.3 (5.89) 22 9.2 (37.90) .965 .438 .234
Glucose, mmol/L 25 5.4 (2.80) 25 4.8 (0.94) 23 5.0 (0.88) 22 4.9 (0.88) .827 .571 .480
Serum triglycerides 26 23 20 22 .781 .027 .072
 mmol/L 0.52 (0.16) 0.54 (0.19) 0.69 (0.38) 0.67 (0.36)
 mg/dL 46.02 (14.16) 47.79 (16.81) 61.06 (35.40) 59.29 (30.10)
Total cholesterol, mmol/L 26 3.1 (0.91) 22 3.1 (0.90) 12 3.9 (0.86) 13 3.0 (0.74)
f .060 .034 .652
Ratio LDL/HDL cholesterol,  
 g/cm (IU/L) 24 1.22 (0.59) 22 1.18 (0.54) 12 1.89 (0.68) 13 1.48 (0.64) .160 .014 .820
HDL cholesterol, mmol/L 25 1.4 (0.51) 23 1.4 (0.44) 12 1.3 (0.25) 13 1.1 (0.28) .742 .182 .232
LDL cholesterol, mmol/L 24 1.5 (0.70) 22 1.5 (0.61) 12 2.3 (0.73) 13 1.6 (0.64) .080 .040 1.000
Values presented as mean (SD). All comparisons of change from baseline (within and between groups) are based on patients with 
pairwise available data. ALT, alanine 3aminotransferase; CRP, C-reactive protein; GGT, glutamyl transpeptidase; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein.
aBetween-groups comparison of change from baseline, Wilcoxon test.
bWithin-groups comparison (baseline vs day 8), Wilcoxon signed rank test.
cBaseline value = day 3.
eBaseline value = day 5.
dFinal value = last visit.
fBetween-groups comparison on day 8, P < .05.88S  Journal of Parenteral and Enteral Nutrition / Vol. 36, Suppl. 1, January 2012
regard to the mean increase in triglycerides from baseline 
to day 8/LVCF (0.18 ± 0.35 vs 0.09 ± 0.33 mmol/L 
corresponding to 15.93 ± 30.97 vs 7.96 ± 29.20 mg/dL, 
test vs control, P = .702, Wilcoxon test). Accordingly, 
least squares means of change from baseline showed no 
noteworthy differences between groups (ITT) when 
adjusted for baseline and covariates (age, stratum, Apgar 
score). The test result for the confirmatory analysis was 
MW = 0.4659 [0.3119; 0.6267]. Because the lower limit 
of the confidence interval was below the lower equiva-
lence margin of 0.38, according to the benchmarks 
defined by Colditz et al,
22 noninferiority of the study 
treatment could not be demonstrated in a confirmatory 
sense.
On day 8, body weight was significantly increased vs 
baseline in both treatment groups (baseline/day 1: 1359 ± 
311 g vs 1278 ± 295 g; day 8: 1394* ± 355 g vs 1381* ± 
330 g; test vs control; *P < .01 day 8 vs baseline within 
group). Changes from baseline were similar between 
groups (95.18 ± 123.81 vs 118.54 ± 84.33 g, test vs con-
trol, P = .59). Daily weight gain, depending on the respec-
tive body weight up to day 8, was not different between 
groups (13.0 ± 25.5 vs 15.7 ± 11.1 g/kg BW, test vs con-
trol, P = .30).
Body height increased slightly but significantly in 
both treatment groups over the complete study phase 
(baseline: 38.9 ± 3.8 cm vs 39.1 ± 3.2 cm; last observa-
tion: 40.7* ± 3.8 cm vs 40.7* ± 3.3 cm; test vs control; 
*P < .01 last observation vs baseline within group). 
Changes from baseline were similar between groups (P = 
.89). Least squares means of change from baseline 
showed no noteworthy differences between groups with 
regard to body weight as well as to body length (ITT) 
when adjusted for baseline and covariates (age, stratum). 
Analysis of the PP population (data not shown) revealed 
the same pattern as for the ITT population.
Secondary Outcome Measures
Mean values for hemoglobin, hematocrit, and red and 
white blood cell count showed a decrease and platelets an 
increase in both groups after the main study phase (Table 
6). Yet, values for changes from baseline to day 8 were not 
significantly different between treatment groups, and 
mean values remained within the normal range with no 
clinical relevancy. Evaluation of lipid parameters revealed 
no significant differences between groups at baseline and 
on study day 8, with the exception of total cholesterol and 
LDL cholesterol on study day 8, which were higher in the 
test group (P < .05 between-groups comparison of change 
from baseline, Wilcoxon test) but still remained within 
normal ranges (Table 6). Clinical laboratory parameters 
changed significantly over the main study phase within 
both groups for alanine aminotransferase (ALT; signifi-
cant increase in both treatment groups) and creatinine 
(significant decrease in both treatment groups). In the 
test group, a significant decrease in total and a slight 
decrease in direct bilirubin levels were observed (Table 
6). In controls, direct bilirubin levels increased signifi-
cantly from baseline to the final observation. For total and 
direct bilirubin levels, the absolute change from baseline 
to last observation was significantly different between 
groups (total bilirubin: –50.3 ± 45.8 vs –18.6 ± 54.2 
µmol/L corresponding to –2.94 ± 2.68 vs –1.09 ± 3.17 
mg/dL; direct bilirubin: –2.22 ± 8.89 vs 4.79 ± 8.38 
µmol/L corresponding to –0.13 ± 0.52 vs 0.28 ± 0.49 mg/
dL, test vs control, P < .05 between-groups comparison of 
change from baseline, Wilcoxon test).
In total, 75 AEs in 29 patients (11 study group/18 
control group) were observed during the treatment 
period—32 in the study and 43 in the control group—
affecting most frequently the system organ class “infec-
tions and infestations” (3/8), including chorioamnionitis, 
bacteremia with or without sepsis, respiratory tract infec-
tions, and conjunctivitis; “hepatobiliary disorder” (4/6), 
including increased total and indirect serum bilirubin 
necessitating treatment (fototherapy or albumin replace-
ment) and increase of direct serum bilirubin (>17.1 
µmol/l and >20% of total bilirubin), serum glutamyl trans-
peptidase (GGT), and ALT that exceeded normal bio-
chemical limits; and “metabolism and nutrition disorders” 
(4/6), including hyperglycemia and metabolic acidosis. 
Most AEs were of mild and moderate intensity; 6 SAEs 
were experienced in the study group and 5 in the control 
group.
During the treatment period, 4 infants (2 in each 
treatment group) experienced serious treatment-emer-
gent AEs (teSAEs) leading to discontinuation of study 
medication, with 2 of them resulting in the death of the 
patient (pneumothorax, test group; enterobacter sepsis, 
control group). Further teSAEs observed included hyper-
glycemia (test group) and staphylococcal sepsis (control 
group). Another 2 patients (1 in each treatment group) 
experienced posttreatment SAEs, one of them (multior-
gan failure, control group) resulting in the death of the 
patient. Almost all SAEs in both treatment groups were 
assessed as “not related to study drug,” with 1 exception 
of enterobacter sepsis in the control group, which was 
rated as “possibly” related to the study drug. Apart from 
the 2 infants who died during treatment and 1 who died 
in the posttreatment phase, all others survived until dis-
charge.
The tolerability of the study treatment was assessed 
as being “very good” or “good”; there was no difference 
between treatment groups. An effect of study medication 
on vital signs (blood pressure, heart rate, body tempera-
ture) pre- and posttreatment was not observed (data not 
shown).
In the test group (n = 26), the number of infants 
receiving supportive or artificial ventilation was 16 during Lipid Emulsion of Soybean, Olive, and Fish Oils and MCT in Preterm Infants / Rayyan et al  89S
the main study phase and 18 over the complete treatment 
period. In controls (n = 27), 18 infants received support-
ive/artificial ventilation during both study phases. Median 
time to end of supportive or artificial ventilation was 2 vs 
3 days (test group vs control group; ITT). Yet, superiority 
of test treatment could not be shown in the Peto log-rank 
test (P = .7986) or the Cox regression model (P = .8239). 
Analysis of the PP population (data not shown) showed 
no significant differences to the ITT population.
Mean baseline values of plasma lipoprotein phos-
pholipid fatty acids shown as relative amounts were very 
similar in both treatment groups (P > .05, Wilcoxon test). 
Fatty acid patterns in plasma phospholipids pre- and post-
treatment and in RBC phospholipids posttreatment are 
shown in Table 7 and Figure 2, respectively.
Discussion
Premature neonates have only limited muscle and fat 
mass and thus decreased hydrolytic capacity of the 
enzyme lipoprotein lipase.
23 As a consequence, they are at 
higher risk for PN-associated hypertriglyceridemia than 
term infants.
1,2 Tight monitoring of serum triglyceride 
levels has been recommended in premature neonates to 
avoid hypertriglyceridemia with the provision of increas-
ing lipid concentrations as recommended by actual PN 
guidelines.
2 Therefore, our primary hypothesis was that, 
in premature neonates, test treatment would not be inferior 
to a standard soybean oil emulsion with regard to the 
serum concentration of triglycerides.
Throughout the study, mean serum triglyceride levels 
remained below the upper limit of normal range (1.6 
mmol/L or 142 mg/dL) in both treatment groups for all 
time points (baseline, day 5, day 8, post day 9, and last 
visit). For the present trial, the benchmark of clinical 
relevance was set at 3.43 mmol/L (304 mg/dL). In the 
meantime, recommendations of ESPEN/ESPGHAN have 
become available that consider a concentration of serum 
triglycerides exceeding 2.82 mmol/L (250 mg/dL) a criti-
cal limit calling for a reduction in parenteral lipid dose.
2
As a result of the lipid infusion, there was a slight 
increase in triglycerides from baseline to day 8 in both 
treatment groups, which was significant in the test group 
(P = .03) and tended to be significant in the control group 
(P = .07) but was not different between groups (P = .15). 
Yet, statistical proof of the noninferiority of the study 
treatment could not be given in a confirmatory sense. 
Possibly, the fact that infants in the test group were 
slightly more immature than control infants might have 
influenced the tolerance to parenteral lipids, explaining 
the failure to give confirmatory proof of the equality of 
treatments administered. Yet, with regard to the critical 
limits, the slight and comparable increase in triglyceride 
concentrations as observed with both study treatments 
(<0.2 mmol/L) may be rated of no clinical relevance, con-
firming the safety of both treatments administered. 
Triglyceride concentrations observed in the present trial 
Table 7.  Fatty Acid Pattern (% of Total Fatty Acids) in Plasma Phospholipids Before and After Study Treatment: 
Intention-to-Treat Population
Pretreatment Posttreatment P
a P
b
n
Test  
Group 
(SMOFlipid) n Control Group n
Test Group 
(SMOFlipid) n Control Group
Test vs 
Control
Test  
Group 
(SMOFlipid)
Control 
Group
C18:1 n-9 (oleic acid) 22 29.84 (4.66) 23 28.04 (4.31) 19 25.72 (2.87) 20 19.48 (2.92)
c .043 .009 <.001
C20:3 n-9 22 1.32 (0.76) 23 1.35 (1.11) 19 0.16 (0.30) 20 0.05 (0.06)
c .987 <.001 <.001
Total n-6 PUFA 22 12.45 (6.49) 23 12.34 (5.51) 19 35.36 (4.54) 20 48.08 (5.81)
c <.001 <.001 <.001
C18:2 n-6 (LA) 22 3.88 (2.82) 23 3.73 (2.33) 19 29.02 (4.92) 20 41.78 (6.66)
c <.001 <.001 <.001
C20:4 n-6 (AA) 22 6.99 (4.17) 23 7.02 (3.46) 19 5.07 (1.17) 20 5.30 (1.55) .477 .263 .036
Total n-3 PUFA 22 1.96 (0.90) 23 1.65 (0.71) 19 4.44 (1.29) 20 2.24 (0.41)
c <.001 <.001 .008
C18:3 n-3 (α-LNA) 22 0.03 (0.03) 23 0.02 (0.02) 19 0.24 (0.09) 20 0.44 (0.20)
c <.001 <.001 <.001
C20:5 n-3 (EPA) 22 0.14 (0.08) 23 0.13 (0.07) 19 1.35 (0.64) 20 0.13 (0.07)
c <.001 <.001 .898
C22:6 n-3 (DHA) 22 1.72 (0.79) 23 1.44 (0.62) 19 2.50 (0.70) 20 1.50 (0.37)
c .002 .001 .609
n-6/n-3 ratio 22 6.67 (2.41) 23 7.65 (2.10) 19 8.50 (2.29) 20 22.04 (4.37)
c <.001 <.001 <.001
Values presented as mean (SD). All comparisons of change from baseline (within and between groups) are based on patients with 
pairwise available data. AA, arachidonic acid; α-LNA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, 
linoleic acid; PUFA, polyunsaturated fatty acid.
aBetween-groups comparison of change from baseline, Wilcoxon test.
bWithin-groups comparison (pre- vs posttreatment), Wilcoxon signed rank test.
cBetween-groups comparison on day 8, P < .05.90S  Journal of Parenteral and Enteral Nutrition / Vol. 36, Suppl. 1, January 2012
are also in line with those reported by Tomsits et al
24 in a 
similar study population, supporting their conclusion that 
a physical mixture of soybean oil, MCTs, olive oil, and 
fish oil is safe and well tolerated in premature infants 
requiring PN.
The significant increase in LDL cholesterol in the 
test group as compared to the controls is not well 
explained and is in contrast with the results obtained in 
the study by Tomsits et al.
24 In this study, no differences 
in HDL and LDL cholesterol were observed. In the 
present study, the values of the LDL/HDL ratio are com-
parable with breastfed preterm infants.
25
For the hematological parameters, changes observed 
after study treatment in both groups might be ascribed both 
to the routine blood sampling and to the physiological ane-
mia frequently experienced by preterm babies.
26,27 Clinical 
laboratory parameters showed no clinically relevant changes 
during the main study phase. Predominantly, values reflect 
the common postnatal development in this patient popula-
tion (eg, maturation of kidney function). Consequently, 
other safety aspects, such as hematological and clinical labo-
ratory parameters, as well as the adverse event profile and 
evaluation of vital signs indicate that both lipid emulsions 
were equally safe and well tolerated over 7–14 days.
Premature neonates with low birth weights, receiving 
PN for longer periods, are at an enhanced risk to develop 
cholestasis and PN-associated liver disease (PNALD).
1,28-
31 Monitoring of total and, in particular, direct bilirubin 
levels during parenteral feeding is thus crucial. In the 
present trial, mean values for direct bilirubin remained 
below the critical level of 17.1 µmol/L and <20% of total 
bilirubin, respectively, before and after study treatment.
31 
Total bilirubin levels decreased significantly in the 
neonates receiving the test mixed emulsion after 7–14 
days of parenteral feeding but not in controls receiving a 
soybean oil–based emulsion. Furthermore, although a 
slight decrease in direct bilirubin could be seen in the test 
group over the treatment period, this parameter showed a 
significant increase in controls. Short-term application of 
the new lipid emulsion was thus associated with benefi-
cial effects on serum bilirubin levels in premature 
neonates, thereby potentially reducing their risk of devel-
oping cholestasis.
The concept that a change in parenteral lipid regimen, 
from a predominance of n-6 fatty acids to lipid emulsions 
containing n-3 fatty acids from fish oil, may be effective in 
the prevention and treatment of PNALD is still under dis-
cussion.
17,32-34 Beneficial effects on liver function with a 
mixed emulsion containing soybean oil, MCT, olive oil, and 
fish oil were observed in a few studies in adult and pediat-
ric patients: in adult intensive care unit patients after 
major surgery, a lower rise in liver enzymes and in the 
phospholipids/plasma apolipoprotein A1 ratio (a surrogate 
marker of liver function) suggested better liver function by 
PN with the test emulsion than with a soybean oil emul-
sion.
35 In postoperative surgical patients, ALT, aspartate 
aminotransferase, and α-glutathione S-transferase levels 
(markers of hepatic integrity) were also significantly lower 
with the test emulsion as compared to a lipid emulsion 
based on olive and soybean oils, indicating a better liver 
tolerability.
36 In a study in children receiving long-term PN 
with the test emulsion, a significant improvement in 
plasma bilirubin could be observed.
37
The present findings must be interpreted with cau-
tion, though, regarding possible benefits of the test lipid 
emulsion on the development of PNALD in premature 
infants. First, the observed reduction in total bilirubin, to 
some extent, reflects the common postnatal development 
in this patient population. Furthermore, patients need to 
be on PN for a longer time before negative effects on liver 
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Figure 2.    Fatty acid pattern in red blood cells after study treatment (% of total fatty acid, mean ± SEM). Striped bars: SMOFlipid, 
solid bars: control. *P < .05 between groups (Wilcoxon test). AA, arachidonic acid; α-LNA, α-linolenic acid; DHA, docosahexaenoic 
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function become apparent, whereas most of the neonates 
in the present trial did not require PN beyond the third 
week of life. Further trials evaluating the potential hepat-
oprotective effects of the new lipid emulsion over pro-
longed periods on a larger number of patients are needed.
Soybean oil–based lipid emulsions contain high 
amounts of γ-tocopherol but relatively low amounts of 
α-tocopherol, the main lipophilic antioxidant. In some 
older studies, infusion of soybean- or safflower–based 
lipid emulsions has been associated with an increased 
production of peroxidative intermediates and, therefore, 
an aggravated risk of oxidative stress.
38,39 Oxidative stress, 
representing a common mediator of the inflammatory 
process, has been associated with hepatocellular injury in 
preterm infants on PN.
40 In previous studies evaluating 
the test emulsion in preterm infants and children, param-
eters of lipid peroxidation did not differ between treat-
ment groups, but vitamin E status and total antioxidant 
potential were significantly improved with the provision 
of adequate amounts of vitamin E as compared to con-
trols receiving a soybean oil emulsion.
24,37,41 Unfortunately, 
measurements of vitamin E status and lipid peroxidation 
were not within the scope of the present investigation. 
However, with regard to the previous finding, it was 
assumed also in the present trial that the provision of 
increased amounts of α-tocopherol with the test emulsion 
may have contributed to protecting the liver against 
PN-induced peroxidative damage. Eventually, the partial 
replacement of soybean oil with fish oil in the new lipid 
emulsion resulted in a lower phytosterol intake in the 
infants receiving the test emulsion. It has repeatedly been 
suggested that phytosterols may represent a further con-
tributing factor to the pathogenesis of PN-related 
cholestasis.
30,42-44 Phytosterol concentrations have been 
shown to be particularly high in plant oil–based lipid 
emulsions, whereas fish oil emulsions are free from phy-
tosterols.
35
In our study, fatty acid profiles were to be measured 
in plasma and in RBC phospholipids pre- and posttreat-
ment. Unfortunately, reliable baseline values for RBC 
fatty acid composition are not available because of diffi-
culties in sample handling that occurred during the isola-
tion of RBCs from the blood samples drawn at baseline. 
Therefore, only posttreatment results are presented for 
RBC phospholipid fatty acid composition.
In both plasma and RBCs, values measured for the 
essential fatty acids LA and α-LNA posttreatment were 
significantly higher in the group receiving the soybean oil 
emulsion than in the infants receiving the test emulsion. 
These findings reflect the different fatty acid composition 
of the investigational lipid emulsions, thereby confirming 
compliance to the treatments administered.
Also, the long-chain homologues of α-LNA (ie, EPA 
and DHA) were significantly increased with the mixed 
fish oil containing test emulsion as compared to controls’ 
posttreatment values. Obviously, the increased provision 
of EPA and DHA with the fish oil component of the 
tested emulsion more than outweighed the decreased 
supply of the precursor fatty acid in both compartments. 
The increased values for EPA and DHA observed in the 
present study are in line with the findings by Goulet et al
37 
in pediatric patients on long-term PN showing signifi-
cantly increased relative amounts of both EPA and DHA 
in plasma and RBC phospholipids after 28 days. Although 
Tomsits et al
24 also recently reported an increase in RBC-
EPA in premature neonates receiving the test emulsion, 
they did not observe a corresponding increase in RBC-
DHA. The reason for this finding could be that the pre-
term neonates in that study received up to a maximum of 
2 g lipids/kg BW/d. In a recent study of preterm infants 
<1250 g receiving a lipid emulsion containing 10% fish 
oil, a decrease of DHA in RBC was noticed.
45 However, 
this was less significantly decreased compared to the 
group receiving a soybean oil–based emulsion.
The significance of these findings has to be related to 
the intrauterine and postnatal accretion of LC-PUFAs in 
preterm and term infants. During the third trimester of 
fetal life, a rapid accretion of DHA, EPA, and AA takes 
place.
46,47 Because of the relatively inefficient endog-
enous conversion of α-LNA to DHA in the newborn, 
there seems to be an apparent need for the supplementa-
tion of preformed LC-PUFAs in preterm infants.
5 It has 
been calculated that the need for supplementation of 
DHA in preterm infants is even higher than actually pro-
vided by the supplemented preterm formulas.
48 It has 
been suggested that enteral feeding supplemented with 
DHA is beneficial for the neurodevelopmental outcome 
of preterm infants.
49 Furthermore, it could be hypothe-
sized that measurements of RBC phospholipids allow 
predictions of this accretion and its potential beneficial 
effect on visual acuity and mental and psychomotor 
development in later infancy.
50 Indeed, an adequate intake 
of dietary DHA and AA seems to be required for optimal 
functional maturation of the retina and visual cortex.
11,51-53 
It is also generally accepted that LC-PUFAs, particularly 
the n-3 LC-PUFA from fish oil, possess potent immu-
nomodulatory and anti-inflammatory properties.
54 A shift 
from a predominance of n-6 fatty acids to n-3 LC-PUFAs 
from fish oil in PN may be effective in modulating the 
eicosanoid profile toward a reduction in circulating levels 
of proinflammatory mediators, thereby potentially con-
tributing to decreasing the risk of hepatic injury.
30 In the 
present trial, C-reactive protein levels showed an increase 
over the main study period in both groups, which was 
distinctly yet not significantly more pronounced in the 
infants receiving the soybean oil emulsion.
In plasma and RBC phospholipids, posttreatment 
values for the long-chain homologue of LA, arachidonic 
acid (AA, C20:4 n-6), were comparable with both lipid 
emulsions, indicating that small amounts of AA (0.5%) 92S  Journal of Parenteral and Enteral Nutrition / Vol. 36, Suppl. 1, January 2012
and LA (18.7%) contained in the test emulsion efficiently 
compensated for the much higher amount of LA (53%) 
contained in the soybean oil emulsion. AA has been 
shown to affect growth and development in early infancy 
in a positive way.
11 Furthermore, the supply of AA in 
preterm infants has been associated with the weight at 
birth and growth during the first year of life.
55 In the pre-
sent trial, both body weight and height were significantly 
increased vs baseline in both treatment groups, independ-
ent of lipid source, suggesting that PN with SMOFlipid, 
providing n-3 fatty acids from fish oil, was equally effec-
tive in promoting growth in premature neonates as a 
conventional soybean lipid emulsion. This finding might 
be of particular interest, taking into account that 2 trials 
published in the 1990s have raised concerns that the use 
of a fish oil–enriched enteral formula might reduce the 
growth of preterm infants.
56,57 It has been shown, how-
ever, that the decrease in weight gain was due to a defi-
ciency in AA in the fish oil–supplemented formula and 
that optimal weight gain requires a well-balanced DHA/
AA. This was confirmed in a recent Cochrane Database 
Systematic Review showing that formula supplemented 
with DHA and AA, with or without EPA, did not impair 
growth.
58 Consequently, recommendations have been 
made about the supply of LC-PUFAs with infant for-
mula.
59,60 Fish oil–based emulsions for PN naturally con-
tain both EPA and DHA. The ESPGHAN guidelines on 
neonatal and pediatric PN have no recommendations on 
the individual LC-PUFAs.
2 The increase of EPA observed 
in this study may be of concern. In a long-term feeding 
study with a formula high in linolenic acid and marine oil 
(without additional AA), plasma and RBC values of EPA 
were far above the values found in the present study.
61 
The follow-up of those children has been the subject of a 
number of studies, with the general conclusion that apart 
from an impaired growth (AA deficiency), the group with 
high marine oil supplementation had a improved visual 
and psychomotor development at 12 months compared to 
the group with standard formulation and comparable 
with breastfed infants.
62-64 A similar increase of EPA in 
plasma and red blood cells has been found in a recent 
study in preterm neonates <1250 g receiving a lipid emul-
sion containing 10% fish oil.
45
The n-6/n-3 fatty acid ratio was significantly lower 
with the test emulsion as compared to controls posttreat-
ment. This reflects the n-6/n-3 fatty acid ratio in the test 
emulsion corresponding to approximately 2.5:1, which is 
in accordance with acknowledged recommendations for 
adults and approximates the ratio in human milk.
49,65,66 In 
contrast, for soybean lipid emulsions, an n-6/n-3 fatty 
acid ratio of 7:1 has been reported.
65 In line with the 
present data, the authors of a clinical study in surgical 
patients have reported significantly higher total n-3 and 
lower total n-6 fatty acids in plasma phospholipids after 5 
days of PN, including the mixed fish oil containing test 
emulsion, resulting in a decreased n-6/n-3 fatty acid ratio 
as compared to a standard soybean oil emulsion.
67 A 
modification of the RBC phospholipid pattern, as indi-
cated by a significantly lower n-6/n-3 fatty acid ratio, 
could be seen in another randomized controlled trial in 
preterm neonates receiving the test emulsion vs a conven-
tional lipid emulsion and in children on long-term PN.
24
As for many clinical studies in a sensitive population 
of preterm infants, this study has a number of shortcom-
ings in addition to the reduced number of patients 
included. A potential source of bias for the present trial 
rests in the fact that neonates in both treatment groups 
received roughly 30% of their total fat intake from enteral 
supplementation. Yet, the results of the present study 
show that changes in the fatty acid profiles occurred con-
siderably faster with PN as compared to the findings of 
investigations with oral supplementation.
50 Possibly, the 
parenteral route might be predominant in comparison to 
the enteral route in achieving relevant increases in 
LC-PUFAs within such a short period. Further investiga-
tions are requested to investigate how long these effects 
can be maintained after the switch from PN to EN in this 
patient setting. A further potential source of imprecision 
might be ascribed to the fact that the number of study 
patients decreased rapidly after treatment day 7. 
Therefore, study variables were evaluated for the main 
study phase but also until completion of PN, with the 
means of the last observation carried forward (LOCF), 
which allowed evaluating the effect of the different lipid 
emulsions in most patients. Furthermore, evaluation of 
baseline characteristics revealed that the rate of females 
in the test group was higher as compared to the control 
group (69.2% vs 40.7%; P = .054). According to clinical 
experience, preterm female neonates generally have a 
more favorable clinical outcome in neonatal care as com-
pared to preterm males. On the other hand, neonates in 
the test group were slightly more immature with regard to 
gestational age, body weight, length, and the age at the 
start of infusions. Consequently, these factors of baseline 
inhomogeneity might have outweighed each other with 
regard to potential bias. Finally, the short study period 
does not allow drawing conclusions on safety when PN is 
used for longer periods in preterm infants.
In conclusion, the new lipid emulsion, based on a 
physical mixture of soybean oil, MCT, olive oil, and fish 
oil, was well tolerated and safe in terms of clinical labora-
tory and hematological parameters, AE profile, and vital 
signs over an infusion period of 7–14 days in preterm 
infants. This emulsion seems to be equally effective in 
providing a balanced fatty acid and effective energy sup-
ply. The primary variable, triglyceride levels, was consid-
ered safety related, and the study revealed no statistical 
difference between the groups, although noninferiority 
on the basis of serum triglycerides could not be shown 
in a confirmatory way. Administration of the test lipid Lipid Emulsion of Soybean, Olive, and Fish Oils and MCT in Preterm Infants / Rayyan et al  93S
emulsion was associated with significantly reduced total 
and slightly reduced direct bilirubin levels, indicating a 
potential beneficial effect of SMOFlipid in terms of choles-
tasis. Furthermore, infusion of the test lipid emulsion was 
equally efficient as a standard soybean emulsion in promoting 
the neonates’ growth while being associated with a modi-
fication of the plasma and RBC fatty acid pattern reflect-
ing the fatty acid composition of the novel lipid emulsion. 
The higher availability of n-3 LC-PUFAs with this emul-
sion might be considered advantageous with regard to 
their postulated role in ensuring adequate brain and reti-
nal development in preterm infants and the postulated 
anti-inflammatory and immunomodulatory role. Further 
studies on longer use and on a larger population are 
needed in preterm infants to confirm the safety and effi-
cacy, as well as its effect on mental and visual develop-
ment of this novel lipid emulsion in neonatal care.
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